ClinicalTrials.gg
SuspendedNCT07084168Updated Nov 16, 2026

Multimedia Aid for Genetic Testing in Gynecologic Oncology

An interventional study of Educational videos and Survey in Ovary Cancer and Endometrial Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Suspended at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Why this study was suspended
Revision

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2024, registered Jul 2025).
Updated Nov 16, 2026Now SuspendedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 275 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
945th of 1,499
30 · median 47
Started
2024
with 78 others
No phase
202 of 1,780
45 open now
Registered
1,698th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 945th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 79 that started in 2024, is one of 202 with no phase, and was the 1,698th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

275 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This pilot study aims to estimate rates of genetic testing in patients with ovarian and endometrial cancer before and after the implementation of educational videos about genetic testing. Subjects will be asked to view one of three videos relevant to their cancer diagnosis and genetic testing, and have the option to complete a brief satisfaction survey. A chart review to evaluate rates of genetic testing ordered and referrals placed to Genetics before and after the implementation of the videos will be conducted.

Up to 15-20% of ovarian cancer and 3-5% of endometrial cancer is due to inherited genetic mutation. Given this association, the National Comprehensive Cancer Network (NCCN) recommends genetic counseling and testing for all individuals with a diagnosis of ovarian cancer and endometrial cancer. Some challenges to obtaining genetic counseling and testing include missed identification and referral of eligible patients by providers, lack of provider knowledge, and busy clinic visits limiting time for informed consent and maintaining patient autonomy for genetic testing. Although heterogeneous, the literature supports multimedia use in cancer genetics. However, there is a paucity of data in the field of gynecologic oncology for the role of integrating a multimedia approach to genetic counseling.

03

Conditions studied

  • Ovary Cancer
  • Endometrial Cancer

Keywords

  • genetic testing
  • video implementation
  • chart review
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.

  • Reviewed to participate in the study.
  • Subject is willing and able to comply with study procedures based on the judgment of the investigator.
  • Age ≥ 18 years at the time of consent.
  • Diagnosis of ovarian cancer or endometrial cancer
  • Eligible for genetic testing
  • English or Spanish is the primary language

Exclusion criteria

Exclusion Criteria:

  • Previously completed genetic testing
  • Did not receive initial cancer-directed treatment at study site
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Genetic Testing Awarness

    Educational videos about genetic testing will be provided for ovarian cancer and endometrial cancer.

    Behavioral: Educational videos · Behavioral: Survey

Interventions

  • BehavioralEducational videos

    Educational videos about genetic testing will be provided. Subjects will be asked to view one of three videos (an endometrial cancer/Lynch Syndrome video or a longer or shorter version of an ovarian cancer video) relevant to their cancer diagnosis and genetic testing.

    Also known as: Genetic testing information

  • BehavioralSurvey

    Subjects will be asked to complete a brief satisfaction survey.

06

What researchers measure

Primary outcomes

  1. Proportion of genetic testing

    Proportion of eligible patients undergoing any genetic testing before and after the implementation of educational videos.

    Time frame: Baseline

Secondary outcomes

  1. Overall rates of genetic testing

    Overall rates of genetic testing before and after the implementation of multimedia videos for patient education.

    Time frame: Baseline

  2. Patient satisfaction

    Total scores on patient satisfaction will be measured by a survey. Items are rated by patients on a Likert scale from 1 to 5. Higher scores represent better satisfaction.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Oct 10, 2024
Primary completionEst.
Oct 30, 2027was Oct 2026
CompletionEst.
Oct 30, 2027was Oct 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended Revision
changed Nov 16, 2026
Primary completion
Oct 30, 2026→Oct 30, 2027
Nov 16, 2026
Study completion
Oct 30, 2026→Oct 30, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Suspended
    Why stopped Revision
    Primary completion Oct 30, 2026→Oct 30, 2027
    Study completion Oct 30, 2026→Oct 30, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07084168
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Oct 10, 2024
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Katherine Tucker, MD
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion